Fludarabine, Pixantrone and Rituximab vs Fludarabine and Rituximab forRelapsed or Refractory Indolent NHL
Status:
Withdrawn
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
BBR 2778 is a novel aza-anthracenedione that has activity in experimental tumors and reduced
delayed cardiotoxicity in animal models compared to reference standards. This cytotoxic agent
has structural similarities to mitoxantrone as well as general similarities to anthracyclines
(such as the tricyclic central quinoid chromophore7).
This phase III study will compare the efficacy and safety of the combination BBR 2778,
fludarabine, and rituximab with the combination fludarabine and rituximab in patients with
relapsed or refractory indolent non-Hodgkin's lymphoma.